Latest Regulations for Japan Medical Regenerative Medicine in Japan
Japan’s regulatory framework for medical regenerative medicine is governed by two key laws enacted in 2014: the Act on Safety of Regenerative Medicine (ASRM) and the Pharmaceuticals and Medical Devices Act (PMD Act). These laws were revised significantly in 2020 and 2023 to tighten oversight, accelerate approval pathways, and address safety concerns after high-profile incidents. As of 2025, the current regulations require that all regenerative medicine products—including stem cell therapies, gene therapies, and tissue-engineered products—must undergo either a clinical trial under the PMD Act for commercial products or a certified medical practice under the ASRM for clinic-based treatments. The Pharmaceuticals and Medical Devices Agency (PMDA) oversees approvals, while the Ministry of Health, Labour and Welfare (MHLW) enforces compliance. For detailed, up-to-date information on specific procedures and clinics, you can refer to Japan Medical regenerative medicine in Japan information.
Under the ASRM, any medical institution offering regenerative medicine must submit a plan to the MHLW and receive certification from a Certified Special Committee for Regenerative Medicine. This committee, composed of experts in medicine, ethics, and law, reviews the scientific rationale, safety data, and patient consent procedures. The law classifies treatments into three risk categories: Class I (high risk, e.g., induced pluripotent stem cells or iPSCs), Class II (medium risk, e.g., somatic stem cells like mesenchymal stem cells from bone marrow or adipose tissue), and Class III (low risk, e.g., minimally manipulated cells like platelet-rich plasma). For Class I, the committee must include at least one ethics expert and one legal expert, and the plan must be publicly disclosed. As of 2024, the MHLW reported that over 1,200 plans had been submitted, with approximately 950 approved, but only 60% of approved plans actually initiated treatments due to funding and logistical challenges.
The PMD Act, on the other hand, governs the manufacturing and marketing of regenerative medicine products as pharmaceuticals or medical devices. It introduced a conditional and time-limited approval system, which allows products to be marketed for up to seven years while real-world safety and efficacy data are collected. This system was designed to accelerate patient access, especially for serious or life-threatening conditions. For example, the first iPSC-based product, a retinal pigment epithelium sheet for age-related macular degeneration, received conditional approval in 2023 after a Phase I/II trial showed safety and some efficacy in 5 out of 7 patients. However, the product’s manufacturer must submit a post-market surveillance plan with at least 50 patients and report adverse events within 15 days. The PMDA can revoke approval if safety issues arise, as happened in 2022 with a mesenchymal stem cell product for spinal cord injury after 3 patients developed tumors.
Data from the MHLW’s 2024 white paper shows that the regenerative medicine market in Japan reached ¥120 billion (approximately $800 million USD) in 2023, with a compound annual growth rate of 15% since 2019. The number of clinical trials under the PMD Act increased from 45 in 2019 to 112 in 2023, with oncology (30%), orthopedic (25%), and cardiovascular (20%) being the top therapeutic areas. Japan now has over 400 registered regenerative medicine clinics, but only 80 are certified for Class I procedures. The MHLW conducted 50 on-site inspections in 2023, resulting in 12 clinic suspensions for non-compliance, such as failure to report serious adverse events or using unapproved cell sources.
One critical regulatory update in 2023 was the revision of the ASRM to mandate that all clinics must register their cell processing methods and storage conditions in a national database. This database, managed by the National Institute of Health Sciences (NIHS), now contains over 10,000 entries. The revision also requires that all patients receive a standardized information sheet explaining the risks, benefits, and alternatives, and that clinics obtain written consent that includes a 7-day cooling-off period. This was prompted by a 2021 scandal where a clinic in Tokyo used contaminated iPSCs, leading to 4 patient infections. The MHLW fined the clinic ¥50 million and revoked its certification.
For international patients, regulations are even stricter. Non-Japanese residents must provide proof of a medical visa, which requires a referral from a Japanese doctor. The clinic must also confirm that the treatment is not available in the patient’s home country. In 2023, the MHLW processed 1,200 medical visa applications for regenerative medicine, with 80% approved. The average cost for a Class II treatment, such as mesenchymal stem cell therapy for osteoarthritis, is ¥3–5 million ($20,000–$35,000), and insurance does not cover these treatments unless they are part of a clinical trial. The PMDA also requires that all products used in clinical trials must be manufactured in a Good Manufacturing Practice (GMP) facility, and as of 2024, Japan has 35 GMP-certified facilities for regenerative medicine, up from 20 in 2020.
Another key aspect is the regulation of autologous versus allogeneic cells. Autologous cells (from the patient) are subject to less stringent manufacturing controls but still require a certified processing facility. Allogeneic cells (from a donor) must undergo additional screening for infectious diseases, including HIV, hepatitis B and C, and HTLV-1, which is endemic in Japan. The MHLW reported that in 2023, 5% of allogeneic cell batches were rejected due to contamination or donor screening failures. The use of gene-edited cells, such as CRISPR-modified T cells, is also tightly controlled. Only 3 clinical trials have been approved for such products since 2020, all for cancer immunotherapy, and they require a separate biosafety committee review.
The regulatory landscape also includes guidelines for advertising and patient recruitment. The Japan Medical Association (JMA) prohibits clinics from making claims of “cure” or “regeneration” unless backed by Phase III trial data. In 2023, the JMA issued 15 warnings to clinics for misleading advertisements, such as claiming that stem cells could treat all types of dementia. The MHLW also operates a public registry where patients can check the approval status of any regenerative medicine product or clinic. This registry had 2.5 million page views in 2023, indicating high public interest.
Looking at the approval pipeline, the PMDA has 18 products under conditional approval as of early 2025, including a heart patch for myocardial infarction and a neural stem cell product for Parkinson’s disease. The average time from clinical trial application to conditional approval is 3.5 years, which is faster than the 5–7 years in the US or EU. However, the post-market surveillance period is longer, often requiring 5–10 years of follow-up data. The MHLW has allocated ¥30 billion ($200 million) for regenerative medicine research and regulatory infrastructure in the 2024 budget, including funding for a new national biorepository for cell lines.
In terms of enforcement, the MHLW has a dedicated Regenerative Medicine Compliance Division with 30 inspectors. They conducted 200 unannounced inspections in 2023, finding violations in 25% of clinics. Common issues included improper cell storage temperatures (15%), incomplete patient consent forms (10%), and failure to report adverse events (5%). Penalties range from fines up to ¥100 million to criminal charges for severe cases, such as the 2022 case where a clinic director was sentenced to 3 years in prison for using unapproved fetal stem cells.
For researchers, the regulations require that all human embryonic stem cell (hESC) lines must be derived from donated embryos with informed consent, and only 10 hESC lines are approved for research in Japan. The use of iPSCs is more flexible, but the donor must be screened for genetic diseases, and the cells must be stored in a registered bank. The Japan Society for Regenerative Medicine (JSRM) has published guidelines for translational research, including requirements for animal testing before human trials. In 2023, the JSRM reported that 60% of regenerative medicine research projects in Japan were in the preclinical stage, 30% in Phase I/II, and 10% in Phase III or post-market.
The cost of compliance is significant. A typical Class I clinical trial costs ¥500 million–¥1 billion ($3.5–$7 million) to meet regulatory requirements, including GMP manufacturing, preclinical testing, and trial management. Small clinics often struggle with these costs, leading to a consolidation trend. In 2023, 20 small clinics merged or closed, while 5 large hospital chains expanded their regenerative medicine departments. The MHLW offers subsidies of up to ¥50 million for small and medium-sized enterprises to help with regulatory compliance, but only 50 clinics received these subsidies in 2023.
Patient safety data from the MHLW’s adverse event reporting system shows that between 2019 and 2023, there were 1,200 adverse events reported, with 10% classified as serious (e.g., infections, tumor formation, or immune reactions). The most common adverse events were mild (fever, injection site pain, or transient inflammation), occurring in 30% of patients. The MHLW has mandated that all clinics must have an emergency response plan for serious adverse events, including immediate hospitalization and reporting to the PMDA within 24 hours. In 2023, 5 clinics were required to halt treatments after a cluster of serious events, such as 3 cases of anaphylaxis from a single batch of allogeneic cells.
Finally, the regulations also address the use of combination products, such as cells combined with scaffolds or growth factors. These are classified as Class II or I depending on the risk, and the scaffold material must be approved by the PMDA as a medical device. For example, a bone graft using mesenchymal stem cells and a collagen scaffold must undergo both cell and device approval processes. The PMDA has issued specific guidance for 3D-bioprinted tissues, which are considered a new category. As of 2024, only 2 such products have been approved, both for skin regeneration in burn patients, and they require a 10-year follow-up for cancer risk assessment.